Comparison of the Efficacy and Safety of Axi-Cel and Tisa-Cel Based on Meta-Analysis
(1) Liao C (2) Zeng L (3) Lu S (4) Zheng S (5) Guo B (6) Ke Q (7) Wang M (8) Sun J (9) Rong C (10) He S (11) Zhong D (12) Huang M (13) Tan X (14) Cen H
(1) Liao C (2) Zeng L (3) Lu S (4) Zheng S (5) Guo B (6) Ke Q (7) Wang M (8) Sun J (9) Rong C (10) He S (11) Zhong D (12) Huang M (13) Tan X (14) Cen H
This study aimed to analyze the efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy for B-cell lymphoma using published literature data. Literature on CAR-T therapy for B-cell lymphoma was collected by searching common databases. The literature was screened, quality assessed, and data extracted according to the inclusion and exclusion criteria. We performed a quantitative meta-analysis of the efficacy and safety of combined literature data. If the data could not be combined, descriptive analysis was performed. The meta-analysis results indicated that compared with tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel) had higher objective response rate (ORR) and complete response rate, with odds ratio (OR) of 0.63 for both sides (95% confidence interval [CI], 0.50-0.79) and statistically significant differences. Partial response rate was lower with axi-cel than with tisa-cel, with an OR of 1.02 for tisa-cel versus axi-cel (95% CI, 0.75-1.40) and no statistically significant difference. Compared with tisa-cel, axi-cel had longer progression-free survival and overall survival, with risk ratios of 0.70 (95% CI, 0.62-0.80) and 0.71 (95% CI, 0.61-0.84) for axi-cel and tisa-cel, respectively. Compared with tisa-cel, axi-cel had higher incidence rates of cytokine release syndrome (CRS) and immune effector cell-related neurotoxicity syndrome (ICANS), with ORs of 3.84 (95% CI, 2.10-7.03) and 4.4 (95% CI, 2.81-6.91), respectively. CAR T-cell therapy is an effective treatment option for relapsed/refractory B-cell lymphoma. Axi-cel has better ORR and survival advantages compared with tisa-cel; however, axi-cel has higher incidence rates of CRS and ICANS compared with tisa-cel.
Author Info:
(1) Department of Hematology/Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, China. State Key Laboratory of Targeting Oncology, Guangxi Medical Univ
ersity, Nanning, Guangxi, 530021, China. (2) Department of Hematology/Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, China. Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Guangxi, Nanning, 530022, China. (3) Department of Pharmacy Foresea Life Insurance Guangxi Hospital, Nanning, Guangxi, 530200, China. (4) Department of Hematology/Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, China. (5) Department of Hematology/Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, China. (6) Department of Hematology/Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, China. (7) Department of Hematology/Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, China. (8) Department of Hematology/Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, China. (9) Department of Hematology/Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, China. (10) Department of Hematology/Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, China. (11) Department of Hematology/Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, China. (12) College of Oncology, Guangxi Medical University,Nanning, Guangxi, 530021, China. (13) Department of Hematology/Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, China. (14) Department of Hematology/Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, China.
Citation: J Cancer 2024 15:5729-5741 Epub09/09/2024
